A phase I/III multicenter, randomized, double-blinded, active-controlled study of efficacy and safety of HU-014 in comparison with onabotulinumtoxin A in subjects with moderate-to-severe Crow's Feet Lines
Latest Information Update: 01 Sep 2021
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles
- Focus Therapeutic Use
Most Recent Events
- 01 Sep 2021 New trial record